• A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis

    1 month ago - By Springer

    Abstract
    After the identification of specific epidermal growth factor receptor -activating mutations as one of the most common oncogenic driver mutations in non-small cell lung cancer , several EGFR-tyrosine kinase inhibitors with different clinical efficacies have been approved by various health authorities in the last two decades in targeting NSCLC harboring specific EGFR-activating mutations. However, most patients whose tumor initially responded to the first-generation EGFR-TKI developed acquired resistance. In this study, we developed a novel combination strategy, “antiADAM17 antibody...
    Read more ...